BPTH Bio-Path Holdings Inc.

6.79
-0.28  -4%
Previous Close 7.07
Open 7.05
Price To Book 1.22
Market Cap 25,067,709
Shares 3,691,857
Volume 146,039
Short Ratio
Av. Daily Volume 180,078
Stock charts supplied by TradingView

NewsSee all news

  1. Bio-Path Holdings Provides Clinical Update and 2020 Business Outlook

    HOUSTON, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted

  2. Bio-Path Holdings Announces Successful Completion of Safety Testing in Stage 2 of Phase 2 Clinical Trial in Acute Myeloid Leukemia

    HOUSTON, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted

  3. Bio-Path Holdings Announces Closing of $8.0 Million Registered Direct Offering Priced At-the-Market

    HOUSTON, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted

  4. Bio-Path Holdings Announces $8.0 Million Registered Direct Offering Priced At-the-Market

    HOUSTON, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted

  5. Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002

    HOUSTON, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2a trial to commence in 2020.
Prexigebersen
Chronic myelogenous leukemia (CML)
Phase 2 commencement of dosing announced August 26, 2019.
Prexigebersen - BP1001 + Decitabine + Venetoclax
Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)
Phase 1 trial to commence late-2020 or 2021.
BP1003
Pancreatic cancer
Phase 1 trial to be initiated in 1H 2020.
BP1002
Refractory/relapsed lymphoma and chronic lymphocytic leukemia

Latest News

  1. Bio-Path Holdings Provides Clinical Update and 2020 Business Outlook

    HOUSTON, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted

  2. Bio-Path Holdings Announces Successful Completion of Safety Testing in Stage 2 of Phase 2 Clinical Trial in Acute Myeloid Leukemia

    HOUSTON, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted

  3. Bio-Path Holdings Announces Closing of $8.0 Million Registered Direct Offering Priced At-the-Market

    HOUSTON, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted

  4. Bio-Path Holdings Announces $8.0 Million Registered Direct Offering Priced At-the-Market

    HOUSTON, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted

  5. Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002

    HOUSTON, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted

  6. Bio-Path Holdings Reports Third Quarter 2019 Financial Results

    HOUSTON, Nov. 15, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted

  7. Bio-Path Holdings to Announce Third Quarter 2019 Financial Results on November 15, 2019

    HOUSTON, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted

  8. Bio-Path Holdings Appoints Martina Molsbergen to Board of Directors

    HOUSTON, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted

  9. Bio-Path Updates Intellectual Property Portfolio with Addition of Recently Issued Second Platform Technology Patent

    HOUSTON, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of

  10. Bio-Path Holdings to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    HOUSTON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of

  11. Bio-Path Announces Patient Dosing in Amended Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia

    HOUSTON, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted